Tempus AI, Inc. (NASDAQ:TEM) Stock Holdings Lessened by Geode Capital Management LLC

Geode Capital Management LLC cut its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 0.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 132,555 shares of the company’s stock after selling 616 shares during the period. Geode Capital Management LLC owned about 0.08% of Tempus AI worth $4,475,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Farther Finance Advisors LLC acquired a new position in Tempus AI in the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC lifted its holdings in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares during the last quarter. First Horizon Advisors Inc. boosted its position in Tempus AI by 207.9% during the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock valued at $55,000 after purchasing an additional 1,108 shares during the period. FNY Investment Advisers LLC bought a new position in Tempus AI during the 4th quarter worth $67,000. Finally, IFP Advisors Inc acquired a new stake in Tempus AI in the fourth quarter worth $76,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $52.90 on Friday. The business has a fifty day simple moving average of $49.92 and a 200-day simple moving average of $50.45. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $70.00 price target on shares of Tempus AI in a report on Thursday. BTIG Research assumed coverage on shares of Tempus AI in a research note on Monday, April 21st. They set a “buy” rating and a $60.00 target price for the company. Wolfe Research lowered shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. William Blair reiterated a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Finally, JPMorgan Chase & Co. lowered Tempus AI from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $50.00 to $55.00 in a report on Tuesday, February 25th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $61.08.

Insider Buying and Selling at Tempus AI

In related news, EVP Andrew Polovin sold 13,135 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $45.98, for a total value of $603,947.30. Following the sale, the executive vice president now directly owns 154,171 shares in the company, valued at $7,088,782.58. The trade was a 7.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Erik Phelps sold 5,934 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $67.57, for a total transaction of $400,960.38. Following the sale, the executive vice president now owns 214,662 shares of the company’s stock, valued at $14,504,711.34. The trade was a 2.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 4,584,252 shares of company stock valued at $272,870,580. 27.60% of the stock is owned by insiders.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.